In our previous papers1,2), we reported that antibiotic-producing strains of actinomycetes have individual patterns of antibiotic resistance, depending on the type of antibiotic they produce. In addition, strains with multiple resistance to a wide range of antibiotics were found to have a high probability of antibiotic production. It was therefore expected that the selection of new actinomycete clones with new patterns of resistance to wide ranges of antibiotics might result in the discovery of new antibiotics. In native resistance pattern to streptomycin (SM) and kanamycin (KM), istamycin (IS)-producing Streptomyces tenjimariensis SS-939 was found to be reciprocal with SM-producing S. griseus SS-11982). By taking advantage of this native difference between two strains, antibiotic non-producing mutants derived from both strains were subjected to an interspecific protoplast fusion treatment. This resulted in SMrKMr clones with new antibiotic productivity. This paper describes the generation of such clones and the partial characterization of the antibiotic produced by a selected SMrKMr strain SK2-52.
Materials and Methods
Parent Strains Antibiotic non-producing strains, S. tenjimariensis NM16 and S. griseus NP1-1 were obtained from IS-producing S. tenjimariensis SS-939 and S. griseus SS-1198, respectively, by UV irradiation. The former was resistant to KM (3,000 ,sg/ml) but sensitive to SM (2 yg/ml). The latter was resistant to SM (400 yg/ml) but sensitive to KM (5 yg/ml).
Protoplast Formation S. tenjimariensis NM16 was cultivated in a medium consisting of glucose 5.0 g, Polypepton 2.5 g, yeast extract 0.5 g and glycine 5.0 g in 1,000 ml of 1/2 x Jamarine artificial sea water (pH 7.2, Jamarine Ltd., Osaka, Japan). S. griseus NP1-1 was cultivated in Tryptic Soy Broth (Difco) supplemented with 0.9 % of glycine. Cultivation was carried out at 27°C on a rotary shaker (180 rpm). Mycelia of the two strains at logarithmic growth phase were protoplasted according to the method of OKANISHI et al.3> with a minor modification. S. tenjimariensis NM 16 was incubated with 1.5 mg/ml of lysozyme at 32°C for 90 minutes to obtain about 2 x 109 protoplast cells from 50 ml cultured broth. S. griseus NP1-1 was incubated with 1.0 mg/ml of lysozyme at 32°C for 60 minutes to obtain about 6 x 1010 protoplast cells from 50 ml cultured broth.
Fusion Treatment Protoplasted cells (approximately 1 x 109 for each) from the two strains were suspended in 0.1 ml of medium P3) and incubated for 3 minutes at room temperature after mixing with 0.9 ml of PEG 4000 solution. The solution consisted of 4.O g of PEG 4000 dissolved in 6 ml of in which 25 mm 3-cyclohexylimino-l-propanesulfonic acid (pH 10.5) was used instead of 25 mm 2-[tris-(hydroxylmethyl)methylamino]-1-ethanesulfonic acid (pH 7.2) in medium P. The PEG 4000-treated protoplast cells were then washed with 9 ml of medium P and resuspended in 1 ml of medium P.
Regeneration after Fusion Treatment Protoplast regeneration was carried out according to the method of SHIRAHAMA et al.4> but using a modified regeneration medium (R3M) in which 0.555 M sodium succinate and 0.4% of Low Melting Point agarose (B.R.L.) in R3 medium were substituted with 0.4 M sucrose and 0.6% of Low Gelling Temperature agarose (Marine Colloids), respectively. The protoplast suspension after the fusion treatment was serially diluted before plating on R3M medium and incubated for 14 days at 27°C.
Antibiotic Resistance
Spores of regenerated cultures were suspended in 0.85 % NaCI solution and spread on ISP No. 4 agar medium (Difco) containing 10 ,ug/ml of SM and/or KM. After 5 days incubation at 27°C, colonies grown on the media were transferred to fresh ISP No. 4 medium containing both SM and KM to confirm their resistance.
Antibiotic Productivity Clones which showed resistance to both SM and KM were inoculated on agar cylinders (6 mm in diameter and 4 mm in height) of ISP No. 4 medium supplemented with 0.2 % yeast extract. After 7-day incubation at 27°C, antibiotic activity was checked by placing the agar cylinders on the regular antibiotic assay plate seeded with Bacillus subtilis PCI219 as the test organism.
Characterization of the Antibiotic Produced by the Strain SK2-52 The selected strain SK2-52 was cultured under rotary shaking (180 rpm) for 48 hours at 27°C in medium M consisting of glycerol 20 g, dextrin 20 g, yeast extract 3 g, Bacto Soyton 10 g, (NH4)2SO4 2 g and CaCO3 2 g in 1,000 ml of deionized water (pH 7.4). The filtrate of the cultured broth was chromatographed on XAD-2 and eluted with 40 % acetone. This was followed by chromatography on CMSephadex eluted with a linear gradient of 0.1 ti 0.5 M NaCl.
The active fractions were desalted with XAD-2 and concentrated under vacuum. The crude fraction thus obtained was subjected to high voltage paper electrophoresis5) to compare with the crude extracts of antibiotics produced by S. tenjimariensis SS-939 and S. griseus SS-1198. Bioautography was carried out on an agar plate seeded with B. subtilis PC1219.
Results

Generation of Clones with Resistance to SM and KM by Protoplast Fusion Treatment
After interspecific fusion treatment between S. griseus NP1-1 and S. tenjimariensis SS-939 (1 x 109 protoplast cells of each), about 1.3 x 108 colonies grew up and sporulated on R3M medium. Spores (1.2 x 109) of the regenerated colonies were scraped and plated on ISP No. 4 agar medium containing SM and KM (10 ,ug/ml each). As shown in Table 1 , SMrKMr colonies appeared at a frequency of about THE JOURNAL OF ANTIBIOTICS JAN. 1985 2 x 10-6. The same numbers of colonies were observed on the medium containing only KM. They also proved to be resistant to SM by replica plating. On the other hand, protoplasted cells of each of S. griseus NP1-1 and S. tenjimariensis NM16 were separately subjected to a self-fusion treatment. Interestingly, SMrKMr colonies were obtained from the regenerated culture of S. griseus NP1-1 at almost the same frequency as in the case of interspecific fusion.
Self-fusion treatment of S. tenjimariensis NM16 did not provide any SMrKMr clone. No colonies were observed when about 1 x 109 spores of parental strains without protoplast fusion treatment or protoplast regeneration treatment were plated onto the medium containing KM and SM.
All the SMrKMr clones obtained by the interspecific fusion treatment showed a growth appearance identical with that of S. griseus NP1-1.
Antibiotic Productivity of SMrKMr Clones
Out of SMrKMr clones obtained by interspecific fusion treatment, 1,045 clones were selected at random and examined for the upper limit of resistance to both SM and KM and antibiotic productivity.
The resistance level to SM was the same in all clones (400ug/ml), while they showed different resistance levels to KM. Based on a resistance level to KM of 10, 20 50, or 400 cg/ml, they were roughly divided into three groups with distribution of about 17%, 80% and 4%, respectively (Table 2) . Interestingly, obvious antibiotic production with a 10 to 22 mm inhibition zone by the agar cylinder method was observed only in the group with 20 50 cg/ml resistance to KM at a high frequency (72.7 %). The other 280 colonies sensitive to 10 ug/ml of KM were also picked up after self-fusion of S. griseus NP1-1 and examined for their antibiotic productivity. None of the clones showed antibiotic production.
New Antibiotic Production by a SMrKMr Strain, SK2-52
Among the antibiotic producing SMrKMr strains, strain SK2-52 proved to be the most stable in terms of antibiotic productivity; therefore its antibiotic substance was characterized. When the strain was incubated in medium M, antibiotic production began intensively after about a 24-hour incubation.
Accumulation of the antibiotic reached a peak after a 36 40-hour incubation and then abruptly decreased (Fig. 1) . The filtrate of the cultured broth was active against certain ranges of Gram-positive and Gram-negative bacteria (Table 3) . To characterize the active principle, the filtrate was first chromatographed on an Amberlite IRC-50 (NH4+ or Nat) column which was conveniently used for the extraction of aminoglycoside antibiotics such as IS and SM produced by S. tenjijnariensis SS-939 and S. griseus 
Discussion
On the basis of observations on antibiotic resistance of antibiotic-producing actinomycetesi,2), it was expected that selection of strains with unique multiple antibiotic resistance might result in the discovery of new antibiotics. As described in this paper, selection of clones with resistance to both SM and KM after an interspecific-fusion treatment between protoplasts of S. griseus NP1-1 and S. ten] imariensis NM 16 successfully resulted in the discovery of a novel antibiotic by the strain SK2-52. On the other hand, SMrKMr clones obtained by self-fusion treatment of the above two strains did not result in antibiotic production.
Furthermore, selection of prototrophic clones after interspecific fusion treatment between auxotrophic mutants of S. griseus SS-1198 and S. tenjimariensis SS-939 did not yield new antibiotic production (data not shown). Therefore, it can be concluded that selection using antibiotic resistance after interspecific fusion treatment was effective in obtaining a novel antibiotic-producing clone.
As reported previously1), naturally occurring yellow streptomycete strains rarely show resistance to both SM and KM. Since SMrKMr clones generated after interspecific fusion treatment had a yellow colored growth appearance identical with that of S. griseus, unique resistance patterns to aminoglycoside antibiotics were expected. In fact, the multiple resistance patterns expressed by the SMrKMr clones were not previously observed by naturally occurring streptomycete strains. Therefore, the antibiotic produced by the strain SK2-52 was predicted to be a novel one.
There have been reports on the selection of novel antibiotic-producing clones using auxotrophic markers after an interspecific cross between Streptomyces species8,9) . The antibiotics identified were derivatives of the ones produced by the parental strains. In contrast, the approach described here has provided a novel antibiotic which has no structural similarity to the ones produced by the parental strains as shown in a separate paper7). This approach might be useful for the selection of other novel antibiotics.
The phenotype of the strain SK2-52 caused by the interspecific fusion treatment is characterized in the following paper6). 
